Back Hepatitis B

Hepatitis B

AASLD 2012: When Are HCV Direct-Acting Antivirals Needed, Who Should Be Prioritized?

When resources for hepatitis C treatment with new direct-acting antivirals are limited, findings from the U.S. suggest that previously untreated people with low HCV viral loads may stand a good chance of achieving sustained virological response without adding telaprevir or boceprevir to pegylated interferon and ribavirin, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this month in Boston. A related study suggests that younger hepatitis C patients with advanced liver disease should be prioritized for treatment with the new drugs. alt

Read more:

AASLD 2012: Nucleoside Analogs Reduce Hepatitis B Liver Cancer Risk, Cirrhosis Remains a Concern

Treatment of chronic hepatitis B with nucleoside/nucleotide analogs including lamivudine (Epivir-HBV) and entecavir (Baraclude) can reduce the risk of developing hepatocellular carcinoma, including cancer recurrence after successful resection, according to studies presented at the recent American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) and published in the Journal of the American Medical Association. alt

Read more:

AASLD Liver Meeting Starts this Weekend in Boston

The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting is underway, running November 9-13 at the Hynes Convention Center in Boston. The AASLD meeting each fall and the European Association for the Study of the Liver (EASL) International Liver Congress each spring are the premier events for presentation of the latest data on treatment for hepatitis B and C.alt

Read more:

AASLD 2012: Tenofovir Safe and Effective for Long-term Hepatitis B Treatment with Little Bone Loss

Tenofovir (Viread) continues to be safe and highly effective for treating chronic hepatitis B through 8 years of follow-up, researchers reported at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) this week in Boston. Another study showed minimal bone loss among tenofovir-treated patients using the FRAX method. alt

Read more:

Antiviral Therapy Safe and Effective for Hep B Patients with Advanced Cirrhosis

Antiviral drugs including entecavir (Baraclude), lamivudine (Epivir-HBV), telbivudine (Tyzeka), and tenofovir (Viread) are generally well-tolerated and effective against hepatitis B virus (HBV) in people with liver cirrhosis, and may lower mortality even among patients with severe decompensated cirrhosis, according to 2 recently published studies.alt

Read more:

Coverage of the 2012 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) in Boston, November 9-13, 2012.

Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.

Full listing by topic

HIVandHepatitis.com AASLD 2012 conference section

11/13/12

alt

Registry Data Show Hepatitis B Medications Appear Safe during Pregnancy

An analysis of data from the Antiretroviral Pregnancy Registry found no evidence that pregnant women's use of drugs to treat chronic hepatitis B -- including lamivudine (Epivir) and tenofovir (Viread) -- is associated with birth defects, according to a report in the November 2012 Journal of Hepatology. alt

Read more:

Liver Meeting Highlights: New Hep C Drugs, NAFLD, Liver Cancer, Acetaminophen Toxicity, Benefits of Coffee

The American Association for the Study of Liver Diseases Liver Meeting is the premier annual U.S. conference on althepatology, covering all aspects of liver disease including viral hepatitis, fatty liver, hepatocellular carcinoma, and liver transplantation. Kicking off the meeting on Saturday, AASLD President Guadalupe Garcia-Tsao offered a media overview of some highlights selected from the more than 2000 abstracts to be presented during the week.

Read more:

Hepatitis B Patients with HBeAg Seroconversion on Treatment May Not Have Durable Response

People with chronic hepatitis B virus (HBV) who achieve hepatitis B "e" antigen (HBeAg) seroconversion when treated with nucleoside/nucleotide analogs are more likely to experience HBeAg seroreversion and HBV reactivation than those with natural clearance, according to a study described in the November 15, 2012, Journal of Infectious Diseases.alt

Read more: